India CDMO Market, By Service Type (API (Active Pharmaceutical Ingredients) Manufacturing, Finished Product Manufacturing, Packaging Services, Clinical Research Services (CRO), Laboratory Services), By Application (Generic Drugs, Branded Drugs, Biologics Drugs, Vaccines), By End User (Pharmaceutical Companies, Biotechnology Companies, Research Institutions), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

India CDMO Market was valued at USD 17.51 Billion in 2024 and is expected to reach USD 37.71 Billion by 2030 with a CAGR of 13.60% during the forecast period.

India's Contract Development and Manufacturing Organization (CDMO) sector has emerged as a cornerstone of the global pharmaceutical industry, driven by robust growth and strategic advantages. The country offers a highly competitive manufacturing environment, characterized by cost efficiency, a deep reservoir of skilled scientific talent, and adherence to stringent international regulatory standards. These attributes position India as an indispensable outsourcing hub for leading global pharmaceutical firms.

The sector's trajectory is strongly supported by India's growing expertise in biologics, including vaccines and advanced therapies, as well as government policies that actively foster innovation and infrastructure development. These dynamics solidify India’s standing as a premier destination for pharmaceutical outsourcing, making it a critical partner in the global drug supply chain.

Key Market Drivers

Skilled workforce and scientific expertise

• India’s skilled workforce and scientific expertise remain a core driver of the India CDMO market because the country combines a deep talent pool with strong capabilities in chemistry, formulation development, analytical testing, process optimization, and large-scale commercial manufacturing. This makes Indian CDMOs highly relevant for clients seeking technically capable and cost-efficient outsourcing partners.

• This advantage is especially important in CDMO services, where pharmaceutical and biotech companies want partners that can move efficiently from development to scale-up while meeting stringent quality, compliance, and documentation requirements across regulated markets. India’s long-standing experience in generics, APIs, and increasingly complex therapies strengthens execution reliability and supports faster problem-solving during product development and manufacturing transfer.

• India’s broader pharmaceutical ecosystem further reinforces this strength by supplying trained graduates, researchers, and manufacturing professionals at scale, while decades of industrial experience have built practical scientific know-how that global innovators can access. For instance, Syngene reported in its FY24 annual report that it employed 5,656 scientists and operated about 2 million square feet of specialized research and manufacturing facilities, illustrating the scale of scientific capability available through leading Indian CDMO platforms.

Increasing demand for biologics and specialty drugs

• Increasing demand for biologics and specialty drugs is becoming a major growth engine for the India CDMO market because these therapies require far more sophisticated development, manufacturing, process control, and quality systems than conventional small-molecule products. As global pipelines shift toward high-value targeted therapies, sponsors increasingly need outsourcing partners with stronger technical depth and regulatory readiness.

• India is becoming more relevant in this segment because its CDMOs are expanding biologics infrastructure, strengthening upstream and downstream capabilities, adding fill-finish capacity, and improving compliance frameworks for complex development programs. This is helping the country move beyond traditional pharmaceutical outsourcing into higher-value biologics and specialty drug manufacturing services aligned with global demand trends.

• India’s long experience in vaccines and biosimilars is also reinforcing this opportunity by building technical familiarity with sterile manufacturing, scale-up, and global regulatory standards. That foundation is making Indian CDMOs more attractive for advanced outsourcing mandates.

Rising global healthcare expenditure

• Rising global healthcare expenditure is creating stronger opportunities for the India CDMO market because governments, health systems, and pharmaceutical companies are under greater pressure to expand treatment access while managing development and manufacturing costs more efficiently. This is increasing the appeal of outsourcing to partners that can deliver scale, quality, and speed without developed-market cost structures.

• Indian CDMOs are well positioned in this environment because they offer a combination of established pharmaceutical manufacturing capability, lower operating costs, scientific depth, and growing competence across both traditional and advanced therapeutic segments. As healthcare systems around the world face rising demand from aging populations, chronic disease burden, and more complex therapies, outsourcing to India becomes a practical strategy for cost containment and supply continuity.

• This trend is supported by broader structural increases in healthcare spending, which are reinforcing long-term pharmaceutical demand and manufacturing scale. India also reflects this pattern through rising domestic public health investment, strengthening the overall ecosystem for outsourced development and production. For instance, India’s National Health Accounts show that government health expenditure increased from 1.13 percent of GDP in 2014 to 2015 to 1.84 percent in 2021 to 2022, while its share in general government expenditure rose from 3.94 percent to 6.12 percent.

Download Free Sample Report

Key Market Challenges

Limited Infrastructure for Advanced Therapies

• Limited infrastructure for advanced therapies remains a meaningful challenge for the India CDMO market because the country’s traditional strength has largely been built around small molecules, generics, and conventional formulations rather than biologics, cell and gene therapies, antibody-drug conjugates, and other next-generation therapeutic modalities now attracting global outsourcing demand.

• Moving into advanced therapy segments requires substantial capital investment in cleanrooms, sterile manufacturing systems, containment environments, specialized quality control laboratories, and highly trained technical personnel. Many Indian CDMOs are still building these capabilities gradually, which creates a gap between India’s broad manufacturing reputation and its readiness to support highly complex outsourcing mandates at scale.

• This capability gap becomes more important when global pharmaceutical and biotech clients seek integrated platforms that can handle development, clinical supply, regulatory compliance, and commercial manufacturing within one advanced and tightly controlled operating environment. Without deeper and faster investment, many Indian CDMOs risk remaining concentrated in lower-complexity, lower-margin work while advanced therapy opportunities shift to more specialized international competitors.

• The scale of investment required highlights why infrastructure expansion remains a major barrier for Indian CDMOs seeking to enter high-value biologics and advanced modality segments. For instance, Syngene’s new cGMP mammalian cell manufacturing facility in Bengaluru required an investment of about "Rs " 702 crore and is designed to employ around 100 staff, illustrating how advanced biologics infrastructure demands both heavy capital deployment and specialized operational buildout.

Intense Global Competition and Price Pressure

• Intense global competition and price pressure remain major constraints for the India CDMO market because clients increasingly demand lower costs, faster execution timelines, and higher quality standards at the same time. Meanwhile, competing outsourcing hubs in China, Southeast Asia, and Eastern Europe are also strengthening their capabilities and becoming more attractive alternatives for global pharmaceutical outsourcing.

• In this environment, relying too heavily on cost advantage can create margin erosion and reduce the financial flexibility needed for innovation, regulatory upgrades, capacity expansion, and movement into differentiated services such as biologics, specialty formulations, and other higher-value CDMO offerings. This makes simple price competition an increasingly risky long-term strategy for Indian players.

• The competitive challenge is amplified when Indian CDMOs depend on a relatively concentrated customer base, because pricing renegotiations, project delays, or outsourcing shifts by a few major clients can disproportionately affect revenue visibility, utilization rates, and future investment planning. As a result, customer concentration can heighten vulnerability in periods of aggressive global bidding and procurement pressure.

• These dynamics make differentiation through scientific capability, integrated services, regulatory credibility, and advanced modality support more important than ever for long-term resilience in the India CDMO market. For instance, Sai Life Sciences said in its May 2026 earnings call that its top 10 customers contributed around 40 percent of full-year revenue, highlighting how customer concentration can increase exposure when global competition and price pressure intensify.

Key Market Trends

Integration of Digital and Smart Manufacturing Technologies

• The integration of digital and smart manufacturing technologies is emerging as a defining trend in the India CDMO market as companies invest in automation, connected systems, real-time analytics, and AI-enabled workflows to improve operational efficiency, quality consistency, and turnaround times. This shift is becoming increasingly important as global clients expect faster execution, better control, and higher transparency across outsourced development and manufacturing programs.

• This trend matters especially in regulated environments where delays, deviations, and documentation gaps can create significant cost and compliance risks. Indian CDMOs are responding by digitizing laboratories, implementing electronic documentation systems, and using AI and machine learning tools for predictive modelling, route selection, and process optimization, which helps reduce manual intervention while improving process reliability and decision quality.

• As digital capabilities become more embedded across research and manufacturing operations, smart manufacturing is evolving from a productivity upgrade into a strategic differentiator for Indian CDMOs. It strengthens data integrity, supports better project visibility, and improves client confidence in execution quality. For instance, Aragen says it has built an integrated compound and data management platform across the discovery value chain and deployed AI tools for retrosynthesis along with ML and AI tools for designing novel molecules, while also supporting more than 4,000 scientists globally through its digital and AI-enabled service model.

Rise of Customization and Personalized Medicine

• The rise of customization and personalized medicine is creating an important trend in the India CDMO market as global pharmaceutical pipelines increasingly shift toward targeted therapies designed around specific genetic, molecular, or clinical profiles. This is changing outsourcing requirements because personalized medicine demands greater manufacturing flexibility, smaller production batches, and deeper technical specialization than conventional large-volume pharmaceutical manufacturing models.

• This shift is particularly relevant in segments such as biologics, peptides, oligonucleotides, antibody-drug conjugates, and other advanced modalities, where sponsors need CDMO partners capable of handling complex development, precise process control, and specialized formulation pathways. Indian CDMOs are gradually adapting by moving beyond traditional volume-based manufacturing and investing in integrated development capabilities for more specialized and higher-value therapeutic programs.

• The trend is especially significant in oncology and rare disease treatment, where precision medicine is increasing demand for targeted delivery systems, complex chemistry, and customized process development. This is encouraging Indian CDMOs to broaden service portfolios and align with global innovation trends rather than remain focused only on standard outsourcing work.

Segmental Insights

Service Type Insights

Based on the category of Service Type, the Active Pharmaceutical Ingredient (API) Manufacturing segment emerged as the dominant in the India CDMO Market in 2024. India has long been recognized as the "Pharmacy of the World," with a robust infrastructure for manufacturing APIs. The country accounts for a significant share of the global API supply, catering to markets in the U.S., Europe, and emerging economies.

Indian CDMOs leverage economies of scale and low production costs to offer competitively priced APIs, making them preferred outsourcing partners for global pharmaceutical companies. The presence of state-of-the-art API manufacturing facilities, many of which are certified by international regulatory bodies such as the U.S. FDA and EMA, enhances India’s credibility as a reliable API supplier.

The increasing global demand for generic drugs fuels the need for APIs, a segment in which Indian CDMOs excel. The expiration of patents for blockbuster drugs has further boosted opportunities for API manufacturing in India. Indian CDMOs have a proven track record in producing high-quality generic APIs at scale, making them key players in the global generic drug market. Pharmaceutical companies in developed markets face cost pressures, driving them to outsource API production to cost-efficient locations like India. Indian CDMOs are increasingly adopting vertical integration strategies, encompassing API production, formulation, and finished product manufacturing.

This reduces dependency on external suppliers, particularly for key starting materials (KSMs) and intermediates. With a focus on backward integration, Indian CDMOs have mitigated risks related to supply chain disruptions, especially in light of global challenges like the COVID-19 pandemic. Vertical integration enables end-to-end control over the pharmaceutical production process, increasing efficiency and reducing time-to-market for new drugs. These factors are expected to drive the growth of this segment.

Download Free Sample Report

Regional Insights

South India emerged as the dominant in the India CDMO Market in 2024, holding the largest market share in terms of value. South India is home to key pharmaceutical clusters, particularly in cities like Hyderabad, Bangalore, and Chennai, which are renowned for their advanced infrastructure and global connectivity. These hubs have positioned the region as a focal point for pharmaceutical research, manufacturing, and export.

Known as the bulk drug capital of India, Hyderabad houses numerous API manufacturing units and CDMOs, contributing significantly to the global API supply.  With its strong focus on biotechnology and innovation, Bangalore supports CDMOs specializing in biologics and advanced therapies. Chennai’s proximity to ports and well-developed logistics infrastructure facilitates smooth export operations for pharmaceutical products.

The region benefits from a large pool of skilled professionals, particularly in pharmaceutical sciences, biotechnology, and chemical engineering, supported by prominent educational institutions. Institutions such as the Indian Institute of Technology (IIT) Madras and the National Institute of Pharmaceutical Education and Research (NIPER) in Hyderabad contribute to a highly skilled talent pipeline. Partnerships between academic institutions and CDMOs foster innovation, particularly in drug discovery and formulation development.

Recent Developments

• In March 2025, Shilpa Medicare launched a new full-service “hybrid CDMO” model at DCAT 2025, positioning itself to serve both small-molecule and large-molecule customers as well as peptide programs with a strong oncology focus. Trade coverage said the model combines traditional discovery, clinical, and commercial outsourcing with commercially ready “off-the-shelf” novel formulations available for exclusive B2B licensing, which makes it more flexible than a standard fee-for-service CDMO setup. This was a notable product-and-platform launch in India’s CDMO landscape because it reframed the company’s offering as both a development partner and a source of licensable assets.

• In June 2025, OneSource Specialty Pharma announced a biosimilars manufacturing partnership with Sweden’s Xbrane Biopharma for global markets. According to the company release, OneSource would support manufacturing while the collaboration was intended to strengthen Xbrane’s global supply chain and help OneSource accelerate regulatory clearances, including from the US FDA, for biosimilar production from its Indian platform. This stood out as a meaningful cross-border collaboration because it linked an Indian specialty CDMO with a European biosimilars company to support international commercialization.

• In October 2025, Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions launched an Integrated CMC Partnership to provide innovator biopharma companies with end-to-end chemistry, manufacturing, and controls services. The partners said the arrangement combines Sai’s API development capabilities, Agility’s formulation-development expertise, and Centrix’s drug-product development and clinical manufacturing strengths to help customers move faster from discovery toward the clinic. This qualifies as a significant CDMO collaboration because it created a more unified service pathway for global innovators looking to outsource multiple CMC functions through connected specialists.

• In 2025, Aurigene Pharmaceutical Services expanded its biologics CDMO capacity through a new biomanufacturing facility in Hyderabad’s Genome Valley, strengthening India’s position in higher-value biologics outsourcing. Coverage noted that the facility is designed to manufacture therapeutic proteins, antibodies, and viral vectors while supporting an integrated path from clinical research through commercial manufacturing. This was an important capability innovation for the Indian CDMO sector because biologics capacity remains a strategic differentiator as global outsourcing shifts beyond conventional small molecules.

Key Market Players

• Cipla Limited
• Divi's Laboratories Limited
• Dr. Reddy’s Laboratories Ltd
• Piramal Pharma Limited
• Akums Drugs and Pharmaceuticals Ltd.
• Sunwin Healthcare Private Limited.
• Prakruti Life Science Pvt. Ltd

Report Scope:

In this report, the India CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• India CDMO Market, By Service Type:

o   API (Active Pharmaceutical Ingredients) Manufacturing

o   Finished Product Manufacturing

o   Packaging Services

o   Clinical Research Services (CRO)

o   Laboratory Services

• India CDMO Market, By Application:

o   Generic Drugs

o   Branded Drugs

o   Biologics Drugs

o   Vaccines

• India CDMO Market, By End User:

o   Pharmaceutical Companies

o   Biotechnology Companies

o   Research Institutions

• India CDMO Market, By Region:

o   North India

o   South India

o   East India

o   West India

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the India CDMO Market.

Available Customizations:

 India CDMO market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).